Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Patients with either leukemia or lymphoma were asked if they had close personal associations with other patients before the onset of disease. Iinitial interviews indicated that several patients could be interlinked into social clusters. Tumour-registry records were used to contact each patient (or a surviving relative) diagnosed during the years 1964-73 in three areas of West Virginia. Close personal associations, antedating the onset of disease in 1 or both individuals of each linkage pair, were detected in 14 of 23 (61%), 14 of 22 (68%), and 6 of 8 (75%) patients from these three areas during this ten-year period. In addition, among 28 randomly selected patients with Hodgkin's disease from various parts of the United States, 10 (36%) had direct or indirect close personal associations with 17 other patients with leukemia or lymphoma. Patients with leukemia or lymphoma frequently are interlinked by prior close personal associations to other patients with these diseases.
 ...
PMID:Leukaemia and lymphoma patients interlinked by prior social contact. 4 48

A large inbred family is described in which there were seven cases of Hodgkin's disease, three of lymphosarcoma, two of thymoma, two of common variable immunodeficiency, and single cases of retinoblastoma, neuroblastoma, and rhabdomyosarcoma. There have been no other lymphoma cases in the community during the past decade. Further study of this family may help to define the genetic basis for development of Hodgkin's disease and other disorders.
 ...
PMID:Common variable immunodeficiency, Hodgkin's disease, and other malignancies in a Newfoundland family. 4 22

Surgery, high-energy radiotherapy and cyclic polychemotherapy are best indicated for the treatment of Hodgkin's disease and other forms of lymphoma. Overall evaluation will determine the most suitable management in each case. Clinical andpathological stage, the histological picture, the degree of vascular invasion and the immunological reactivity of the patient are the most important factors in such an evaluation. Close cooperation between the haematologist, histologist, radiologist, surgeon, radiotherapist, pharmacologist and immunologist will obviously be required.
 ...
PMID:[Criteria for choice of therapeutic procedures in lymphomas]. 4 17

The results obtained with intensive chemotherapy and intensive chemotherapy plus radiotherapy in non-Hodgkin's lymphomata are reported. A quintuple drug regimen (mechloretamine, adriamycin, bleomycin, vincristine and prednisone) in histiocytic lymphomata (Stage III and IV) yielded complete remissions in 53% and complete plus partial remissions in 77%. These figures were 44% and 64% respectively in lymphocytic lymphoma. In Stage III complete responders after combination chemotherapy were subsequently irradiated (involved field irradiation). The median duration of complete remission after completion of radiotherapy was 9-5 months in histiocytic and 12-0 months in lymphocytic lymphomata. At 2 years actuarial survival in Stage III and IV was better in patients with the lymphocytic type and with nodular pattern than with histiocytic and diffuse patterns. A more recent trial compares, in Stage IV patients, cyclophosphamide, vincristine and prednisone (CVP) versus adriamycin, bleomycin and prednisone (ABP). Although the number of evaluable patients is still limited, there appears to be no difference in the response rate between CVP and ABP. In Stages I and II, 6 cycles of CVP were given as adjuvant treatment after radiotherapy. At the present moment, there is no statistical difference in the relapse rate between the group of patients treated with radiotherapy alone and that with radiotherapy plus CVP.
 ...
PMID:Combination chemotherapy and radiotherapy in non-Hodgkin's lymphomata. 5 67

Patients presenting with Stage III or IV non-Hodgkin's malignant lymphoma were given chemotherapy; about 20% complete remission was obtained for both stages. The addition of radiotherapy increased the incidence to 70% in Stage III patients. The duration of first complete remission was longer for Stage III (25% of the patients are still in first remission at 7 years) than for Stage IV (0%). The survival was longer for nodular lymphosarcoma patients (25% are alive at 7 years for Stages III and IV) than for diffuse lymphosarcomata and reticulosarcomata (10%). Among the new drugs, VM 26 is able to produce a good frequency of remission in patients in relapse.
 ...
PMID:Non-Hodgkin's malignant lymphomata in adults: chemo-radiotherapy in stages III and IV. 5 69

Several radiopharmaceuticals have recently been shown to have a considerable affinity for malignant tissue. All the tumor-seeking radiopharmaceuticals in current use are nonspecific and may also be picked up by benign tumors and infectious processes, including abscess and granuloma. The sensitivity of the tumor-imaging procedure depends on the radiopharmaceutical employed, the type of tumor, its size and location, and previous or current treatment. Gallium-67 citrate (67Ga), the most widely used tumor-seeking radiopharmaceutical, seems to have its greatest value in detecting bronchogenic carcinomas irrespective of cell type. The sensitivity for lung cancer in 489 studies was 93 per cent. Gallium-67 is also of great value in the staging of Hodgkin's disease, in which its sensitivity is 87 per cent. Non-Hdgkin's lymphomas are detected with only slightly lower sensitivity. There is, in fact, evidence that 67Ga is at least complemenatry, if not more sensitive than lymphangiography, in the staging of lymphoma. However, adenocarcinomas originating in the gastrointestinal tract are detected by 67Ga with a sensitivity of only about 40 per cent, whereas various chelates of bleomycin (including 111In-Bleo, 99mTc-Bleo and 57Co-Bleo) detect adenocarcinoma of the gastrointestinal tract with considerably higher sensitivity. In the few studies available comparing bleomycin chelates, 57Co-Bleo and 99mTc-Bleo appear to be more sensitive in detecting tumor than 111In-Bleo. Other tumor-seeking radiopharmaceuticasl which have been employed with somewhat less success include selenium compounds, labeled pyrimidines, several inorganic cations, lanthanide chelates and labeled proteins. Yet to be evaulated clinically is the efficacy of radiolabeled antibodies which are specific for tumor antigens, such as 131I-anti-CEA (carcinoembryonic antigen).
 ...
PMID:Cancer diagnosis. The role of tumor-imaging radiopharmaceuticals. 5 31

Malignant lymphomas involving major salivary glands have been reported to occur in 31 cases. To these, we add 33 cases, 17 of which were studied in detail from the points of view of clinical presentation, classification (Rappaport), staging (Ann Arbor), therapy, and subsequent course. The parotid gland was involved much more frequently than the submandibular gland. No example of sublingual gland involvement was discovered in the present series. Most of the patients were in the sixth and seventh decades of life. Noteworthy is that all sub-types of lymphosarcoma were encountered, with only a single case of Hodgkin's disease present. In four of the patients, the characteristic histologic picture of lymphoepithelial lesion was found in juxtaposition to malignant lymphoma. The majority of patients received one or more courses of postoperative radiotherapy, which offered the best chance for long-term remission. However, only 40% of patients were free of disease after two years.
 ...
PMID:Malignant lymphomas of the salivary glands. Review of the literature and report of 33 new cases, including four cases associated with the lymphoepithelial lesion. 5 14

Studies were carried out on patients with adverse reactions to aspirin, paracetamol, phenacetin, codeine, dihydrocodeine, some pyrazolone derivatives, and indomethacin. Three clinico-pathological forms of adverse reactions received particular attention: (1) Asthma, with or without manifestations of systemic anaphylaxis; (2) Serum-sickness-like syndrome; (3) Lymph node enlargement with histological features simulating lymphoma or Hodgkin's disease, which occurred in patients receiving phenylbutazone in particular. A variety of immunological investigations, including some in vitro correlates of immediate- or delayed-type allergy, were carried out. The three syndromes seemed to be associated with immediate-type (or immediate-type-like), immediate-type plus delayed-type, and delayed-type allergy, respectively. In most of the patients with immediate-type-like reactions, and where immunological mechanisms were apparently not involved, pharmacological mediators, particularly histamine, were released from their leucocytes when challenged in vitro with the causative agent(s). This suggested that the main underlying abnormality of their asthma or peripheral vascular manifestations was a direct release of mediators by the drugs, i.e. some type of idiosyncrasy. The causative mechanism of this abnormality has not been established yet.
 ...
PMID:Immunological and non-immunological mechanisms of some of the desirable and undesirable effects of anti-inflammatory and analgesic drugs. 6 51

Sixteen patients with Hodgkin's (10) and non-Hodgkin's (6) lymphoma were treated by the "ABCD scheme", which is a combination of adriamycin (25-30 mg/m2 day 1), bleomycin (15 mg day 1-5), CCNU (60 mg/m2 day 1) and DIC (90-100 mg/m2 day 1-5). 15 results are evaluable and included 5 complete remissions, 5 partial remissions, 2 stabilizations, 2 progressions and 1 early death (remission rate: 66%). 45 ABCD courses were given. 8 patients received more than one course (maximum 7 courses). Toxicity was tolerable and consisted mainly of myelodepression, nausea, vomiting and muco-cutaneous alterations. Two patients died following toxicity, one from myelosuppression and the other from interstitial pulmonary fibrosis. The results suggest that this combination can be useful where the usual chemotherapy combination fails.
 ...
PMID:[Simultaneous combination of adriamycin, bleomycin, cyclohexyl-chloroethyl nitrosourea with dimethyl-triazeno imidazole carboxamide in the treatment of Hodgkin's lymphoma]. 6 45

Neoplastic tissues from 75 adults with non-Hodgkin's malignant lymphoma were examined for B and T lymphocyte surface markers. All nodular lymphomas were B-cell type. Of 40 diffuse lymphomas, 23 were B, 5 were T, and 12 were "null" type. Patients with nodular lymphoma survived significantly longer than those with diffuse lymphoma (P = 0-00003). For patients with diffuse lymphoma, however, surface markers provide prognostic information not obtainable by histological classification as "poorly differentiated lymphocytic" or "histiocytic". Patients whose malignant cells had B markers survived significantly longer than those whose malignant cells had no markers (P=O-008). Survival of patients with diffuse lymphoma was best predicted by a classification utilising both surface markers and histological appearances. Differences in survival among patients with B-cell and "null" or T-cell lymphomas may relfect differences in sensitivity to specific drugs.
 ...
PMID:Prognostic significance of lymphocyte surface markers in adult non-Hodgkin's malignant lymphoma. 6 5


1 2 3 4 5 6 7 8 9 10 Next >>